Disc Medicine (IRON) Net Income towards Common Stockholders (2020 - 2026)

Disc Medicine (IRON) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$59.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 7.76% year-over-year to -$59.5 million; the TTM figure through Jun 2026 stood at -$201.4 million (down 38.56% YoY), while the FY2025 annual figure was -$167.7 million, down 53.32% from the prior year.
• Net Income towards Common Stockholders advanced to -$59.5 million in Q2 2026 per IRON's latest filing, from -$63.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$9.6 million in Q2 2022 and bottomed at -$63.6 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$29.1 million across 5 years, with a median of -$25.0 million in 2023.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 48.27% in 2022 and fell as far as 155.29% in 2022.
• Disc Medicine's Net Income towards Common Stockholders stood at -$11.2 million in 2022, then plunged by 109.7% to -$23.6 million in 2023, then retreated by 24.84% to -$29.4 million in 2024, then surged by 45.59% to -$16.0 million in 2025, then sank by 271.7% to -$59.5 million in 2026.
• Business Quant data shows IRON's Net Income towards Common Stockholders at -$59.5 million in Q2 2026, -$63.6 million in Q1 2026, and -$16.0 million in Q4 2025.